Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.
Pier Giorgio CojuttiEzio ZanonSamantha PascaFederico Peanull nullPublished in: Clinical pharmacokinetics (2021)
Intensive FXIII monitoring from day 14, and/or shortening the dosing interval between rFXIII administrations, should be considered to minimise the risk of bleeding.
Keyphrases